Groups | n | SRH at baseline | SRH at 3-yr follow-up | Results paired t-tests | Stability SRH scores | ||||
---|---|---|---|---|---|---|---|---|---|
 |  | M | SD | M | SD | t | d | ICC | 95%CI |
Total sample | 1816 | 5.0 | 1.0 | 5.1 | 1.0 | 3.17 ** | 0.12 | .64 | .62–.67 |
Unaffected during FU | 1126 | 5.4 | 0.8 | 5.4 | 0.8 | 3.71 *** | 0.11 | .57 | .53–.60 |
Occurrence during FU | |||||||||
 MDD | 161 | 4.7 | 0.9 | 4.3 | 1.1 | −5.18 *** | 0.37 | .54 | .39–.67 |
 SAD | 86 | 4.5 | 1.0 | 4.4 | 1.2 | −0.70 ns | 0.08 | .52 | .34–.65 |
Recovery during FU | |||||||||
 MDD | 166 | 4.1 | 1.0 | 4.6 | 1.0 | 6.29 *** | .56 | .57 | .53–.60 |
 SAD | 72 | 4.3 | 1.0 | 4.7 | 1.0 | 3.57 *** | .43 | .63 | .47–.75 |
Chronically affected during FU | |||||||||
 MDD | 94 | 3.8 | 1.2 | 3.8 | 1.2 | 0.27 ns | 0.00 | .54 | .39–.67 |
 SAD | 69 | 4.0 | 1.1 | 4.1 | 1.2 | 1.13 ns | 0.14 | .73 | .60–.82 |